Omeros Other Share Holders Equity 2010-2024 | OMER
Omeros other share holders equity from 2010 to 2024. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
| Omeros Annual Other Share Holders Equity (Millions of US $) |
|
|---|---|
| 2023 | $ |
| 2022 | $ |
| 2021 | $ |
| 2020 | $ |
| 2019 | $ |
| 2018 | $ |
| 2017 | $ |
| 2016 | $ |
| 2015 | $ |
| 2014 | $ |
| 2013 | $ |
| 2012 | $ |
| 2011 | $ |
| 2010 | $ |
| 2009 | $ |
| Omeros Quarterly Other Share Holders Equity (Millions of US $) |
|
|---|---|
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | $0 |
| 2009-03-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.256B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $202.220B | 25.79 |
| Stryker (SYK) | United States | $143.322B | 32.30 |
| Boston Scientific (BSX) | United States | $130.065B | 37.39 |
| Medtronic (MDT) | Ireland | $112.498B | 16.74 |
| EssilorLuxottica (ESLOY) | France | $111.686B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.423B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.501B | 28.26 |
| GE HealthCare Technologies (GEHC) | United States | $39.264B | 20.36 |
| ResMed (RMD) | United States | $37.048B | 30.44 |
| Terumo (TRUMY) | Japan | $29.575B | 41.77 |
| Koninklijke Philips (PHG) | Netherlands | $25.012B | 19.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.536B | 13.71 |
| Insulet (PODD) | United States | $18.791B | 74.86 |
| Baxter (BAX) | United States | $17.673B | 11.51 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.619B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.338B | 35.13 |
| BellRing Brands (BRBR) | United States | $9.136B | 38.63 |
| Demant (WILYY) | Denmark | $8.351B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.084B | 14.14 |
| Haemonetics (HAE) | United States | $4.474B | 21.43 |
| TG Therapeutics (TGTX) | United States | $4.460B | 0.00 |
| ICU Medical (ICUI) | United States | $4.318B | 41.21 |
| Prestige Consumer Healthcare (PBH) | United States | $3.983B | 19.75 |
| Perrigo (PRGO) | Ireland | $3.596B | 10.59 |
| Neogen (NEOG) | United States | $3.517B | 40.57 |
| Envista Holdings (NVST) | United States | $3.509B | 26.14 |
| Agios Pharmaceuticals (AGIO) | United States | $3.368B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $3.041B | 19.50 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.942B | 18.94 |
| LeMaitre Vascular (LMAT) | United States | $2.342B | 56.97 |
| Warby Parker (WRBY) | United States | $1.964B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.888B | 33.04 |
| AtriCure (ATRC) | United States | $1.826B | 0.00 |
| InMode (INMD) | Israel | $1.630B | 9.80 |
| Curaleaf Holdings (CURLF) | Canada | $1.384B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.357B | 9.70 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.280B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.206B | 0.00 |
| Owens & Minor (OMI) | United States | $0.995B | 7.77 |
| Phibro Animal Health (PAHC) | United States | $0.966B | 17.04 |
| CeriBell (CBLL) | United States | $0.962B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.906B | 30.29 |
| Capricor Therapeutics (CAPR) | United States | $0.895B | 0.00 |
| Evolus (EOLS) | United States | $0.866B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.691B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.605B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.582B | 17.56 |
| Quanterix (QTRX) | United States | $0.580B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Valneva SE (VALN) | France | $0.426B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.398B | 0.00 |
| ZimVie (ZIMV) | United States | $0.393B | 33.12 |
| Viemed Healthcare (VMD) | United States | $0.353B | 33.59 |
| Cerus (CERS) | United States | $0.331B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.320B | 21.45 |
| Sanara MedTech (SMTI) | United States | $0.308B | 0.00 |
| Biote (BTMD) | United States | $0.301B | 13.90 |
| Zynex (ZYXI) | United States | $0.287B | 60.07 |
| Jin Medical (ZJYL) | China | $0.284B | 0.00 |
| MacroGenics (MGNX) | United States | $0.273B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.269B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.264B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.236B | 15.90 |
| High Tide (HITI) | Canada | $0.221B | 91.67 |
| Brainsway (BWAY) | Israel | $0.181B | 217.20 |
| Organigram Holdings (OGI) | Canada | $0.172B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.151B | 20.39 |
| Rockwell Medical (RMTI) | United States | $0.137B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.129B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.116B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.111B | 0.00 |
| Veru (VERU) | United States | $0.107B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.104B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 9.82 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.10 |
| Cellectar Biosciences (CLRB) | United States | $0.086B | 0.00 |
| Sanuwave Health (SNWVD) | United States | $0.079B | 2.67 |
| Modular Medical (MODD) | United States | $0.072B | 0.00 |
| InterCure (INCR) | Israel | $0.070B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| MariMed (MRMD) | United States | $0.062B | 0.00 |
| Safety Shot (SHOT) | United States | $0.062B | 0.00 |
| Apyx Medical (APYX) | United States | $0.053B | 0.00 |
| Exagen (XGN) | United States | $0.050B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.048B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.040B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.20 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |